CRL CHARLES RIVER LABORATORIES
2026Q1 · CUSIP 159864107 · Sector: Healthcare & Biotech
Danger · Dual-confirm: breadth + price
Holders
556
Δ holders QoQ
-28
Breadth percentile
Top 95%
Whale holders
231
Δ whales
-7
Inst. holding value
$9.8B
New positions
73
Closed positions
101
Price momentum (1Q)
-5.4%
Put / Call
8/7
Breadth history (34 quarters)
Past Lit Events & Aftermath 14 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2025Q4 | Top 18% | -5.4% | — |
| 2025Q3 | Top 7% | +0.9% | -4.1% |
| 2024Q1 | Top 6% | -7.9% | -15.3% |
| 2023Q3 | Top 15% | +26.0% | +17.7% |
| 2022Q4 | Top 7% | -21.6% | -21.8% |
| 2021Q4 | Top 18% | -26.3% | -27.9% |
| 2021Q3 | Top 2% | -22.7% | -43.0% |
| 2021Q2 | Top 1% | -7.2% | -21.3% |
Options Sentiment
Put holders
8
QoQ: +1
Call holders
7
QoQ: +1
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-3.71
EPS YoY
—
Revenue (TTM)
$4.0B
Revenue YoY
+0.1%
Net margin
-4.6%
ROE
-6.3%
Debt ratio
61.3%
FCF (TTM)
$391M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-28 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.